Moderna-Merck Vaccine Cuts Melanoma Recurrence
Moderna and Merck reported a 42% reduction in melanoma recurrence or death.
October 22, 2026 · Updated Oct 22, 7:54pm ET
Boston GlobeModerna stock plummets even after data confirm cancer vaccine with Merck met key endpoints in melanoma trial
CNBCModerna shares plunge after leak of cancer vaccine data despite positive results
Just the NewsModerna stock plummets after reported leak of disappointing cancer-vaccine data
CNNExperimental mRNA vaccine cuts risk melanoma returns by 42%
ARS TechnicaModerna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Daily MailWorld-first cancer vaccine trial slashes death in research by Aussie
The New York TimesCancer Vaccine Cuts the Risk of Melanoma Recurrence, Merck and Moderna Report
ABC NewsmRNA cancer vaccine helps reduce chances of melanoma patients' tumors returning
Washington TimesA novel mRNA cancer vaccine helps reduce the chances of melanoma patients’ tumors returning
TIME MagazineA Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%
Associated PressA novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning
Scientific AmericanHere’s what Moderna’s latest mRNA cancer vaccine data actually show
STAT NewsDetailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial
MarketWatchModerna’s cancer vaccine hits its targets, but a data leak rattled investors and the stock tumbled
36%
Left · 5
43%
Center · 6
21%
Right · 3
Pano rates the coverage Balanced.
What happened
Moderna and Merck released detailed results from their late-stage melanoma vaccine trial earlier than planned after the data leaked. Their personalized mRNA vaccine, intismeran, given with Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. Intismeran is made for each patient’s tumor, using mRNA to encode tumor markers meant to train immune cells to attack cancer. Moderna shares fell sharply after the leak and early release, despite the positive results. Merck shares also declined. The trial enrolled 1,137 people with high-risk melanoma after surgery. Moderna and Merck said they were working with regulators on approval. Overall-survival results remain outstanding.
How the left told it
Left-leaning outlets framed the results as a cancer-treatment advance, while noting investors punished Moderna anyway. CNN emphasized the vaccine as a path toward a new way to treat melanoma. The Boston Globe centered the contrast between successful trial endpoints and Moderna’s stock drop.
How the right told it
Right-leaning outlets cast the findings as a breakthrough, with extra attention to scientific credit and investor disappointment. The Daily Mail highlighted a new era of personalized cancer vaccines and credited Australian-led science. Just the News stressed that leaked data fell short of market hopes, triggering a Moderna sell-off.
Moderna Merck Melanoma Vaccine Trial
Part of the storyline · Storyline →- Oct 23Moderna Vaccine Shows Phase 3 BenefitBalanced
- Oct 22Moderna-Merck Vaccine Cuts Melanoma Recurrence (this story)Balanced
